Therapeutic Potential of Indole Derivatives as Anti-HIV Agents: A Mini-review. 2022

Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
School of Chemistry and Pharmaceutical Engineering, Huanghuai University, Zhumadian, 463000, China.

Acquired immunodeficiency syndrome (AIDS), caused by the human immunodeficiency virus (HIV), is one of the leading causes of human deaths. The advent of different anti-HIV drugs has turned AIDS/HIV from a deadly infection to chronic and manageable disease. However, the development of multidrug-resistant viruses, along with the severe side effects of anti-HIV agents, has compromised their efficacy and limited the treatment options. Indoles, the most common frameworks in the bioactive molecules, represent attractive scaffolds for designing and developing novel drugs. Indole derivatives are potent inhibitors of HIV enzymes such as reverse transcriptase, integrase, and protease. Furthermore, some indole-based agents, like delavirdine, have already been applied in clinics or are under clinical evaluations for the treatment of AIDS/HIV, revealing that indole moiety is a useful template for the development of anti-HIV agents. This review focuses on the recent advancement in indole derivatives, including indole alkaloids, hybrids, and dimers with anti-HIV potential, covering articles published between 2010 and 2020. The chemical structures, structure-activity relationship, and mechanisms of action are also discussed.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
January 2019, Mini reviews in medicinal chemistry,
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
March 1990, Science (New York, N.Y.),
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
January 2021, Current topics in medicinal chemistry,
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
October 2013, Mini reviews in medicinal chemistry,
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
June 2011, Bioorganic & medicinal chemistry letters,
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
January 2019, Medicinal chemistry (Shariqah (United Arab Emirates)),
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
October 2023, Combinatorial chemistry & high throughput screening,
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
January 2023, Medicinal chemistry (Shariqah (United Arab Emirates)),
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
December 2017, Acta chimica Slovenica,
Qingtai Chen, and Chongchong Wu, and Jinjin Zhu, and Enzhong Li, and Zhi Xu
January 2016, Current pharmaceutical design,
Copied contents to your clipboard!